An interventional study of Probiotic product and Life style modification in Liver Elastography, Liver Steatosis and Liver Function Test, sponsored by Fu Jen Catholic University Hospital. Recruiting at 2 sites in Taiwan. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-06.
Sponsored by Fu Jen Catholic University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Fatty Liver with a site in Taiwan — 8 open to participants now, 10 under way, 5 of them phase 3. Fatty Liver · Taiwan.
Among the 20 studies in Fatty Liver with a site in Taiwan, this one is the 10th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2026, is one of 6 with no phase, and was the 18th registered.
666 studies on the registry are indexed under Fatty Liver; 188 are open to participants now.
Browse Fatty Liver studies →8 of the 20 studies in Fatty Liver with a site in Taiwan are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Taiwan, United States, Argentina and 31 more countries
Ages 18+
National Taiwan University Hospital · Sites in Taiwan
Ages 18+
Taipei Medical University · Sites in Taiwan
Ages 18–80
Boehringer Ingelheim · Sites in Taiwan, United States, Argentina and 34 more countries
Ages 18+
Hoffmann-La Roche · Sites in Taiwan, United States, Argentina and 22 more countries
Ages 18–75
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 118 Fatty Liver studies recruiting now, 36 (31%) set no upper age limit and 63 (53%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 60 across 434 interventional studies indexed under Fatty Liver.
Median enrollment 100 across the 15 interventional studies, 500 across the 5 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 20 have an industry lead sponsor. The 10 most frequent:
Fu Jen Catholic University Hospital is the lead sponsor of 33 studies on the registry; 18 are open to participants now.
Fu Jen Catholic University Hospital has 1 study filed under Fatty Liver — fewer than ten, so there is no comparison to draw.
2 of the studies in Fatty Liver with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07400367Fu Jen Catholic University HospitalImpact of a Probiotic Supplementation With Lifestyle Modification on Liver Steatosis, Fibrosis, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | 2027-05 |
| NCT05956379National Taiwan University HospitalChronic Hepatitis B Patients With Concurrent MAFLD: Cohort Study and Exercise Intervention. | 2027-07-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Fatty Liver with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the new clinical term introduced in 2023 to redefine what was formerly known as Non-Alcoholic Fatty Liver Disease (NAFLD). It is defined as fatty liver confirmed by imaging or biopsy, accompanied by at least one cardiometabolic risk factor (e.g., hyperglycemia, dyslipidemia, hypertension, or obesity). Its pathological progression ranges from simple steatosis to steatohepatitis, primarily driven by excessive energy intake, hepatic lipid accumulation, and insulin resistance.
MASLD is currently the most prevalent chronic liver disease globally, with a prevalence rate of approximately 30-40%. However, there is no satisfactory pharmacological treatment, leaving lifestyle modification as the primary therapeutic approach. Many patients struggle to effectively adjust their habits, leading to persistent hepatic inflammation and damage, which may eventually progress to end-stage diseases such as cirrhosis and hepatocellular carcinoma. In many developed countries, MASLD has become the leading indication for liver transplantation, imposing a heavy burden on healthcare systems.
Gut dysbiosis is closely linked to MASLD. An imbalance in the gut microbiota disrupts the gut-liver axis, leading to impaired intestinal mucosal barrier function. This allows bacterial components to enter the circulation, further triggering hepatic inflammation and abnormal lipid metabolism. Consequently, modulating the gut microbiota is considered a potential therapeutic strategy.
Over the past decade, probiotics, prebiotics, and synbiotics have been extensively studied as non-pharmacological treatments for NAFLD. Multiple studies indicate that these products can reduce liver enzymes (AST, ALT), insulin resistance (HOMA-IR), and inflammatory markers (hs-CRP, TNF-α). The most effective combinations typically involve Lactobacillus, Bifidobacterium, and Streptococcus, with a recommended duration of approximately 12 weeks. However, the impact of these products on liver fibrosis, hepatic fat accumulation, and cardiometabolic risk factors remains inconclusive.
The probiotic product to be tested consists of Lactobacillus salivarius AP-32, Lactobacillus rhamnosus bv-77, Bifidobacterium animalis CP-9, and Lactobacillus reuteri GL-104. This formulation complies with food safety regulations. In clinical studies, it had been proven as an effective adjuvant method that increased beneficial gut bacteria such as Akkermansia muciniphila and improved the control of blood glucose, lipids, and inflammatory markers.
Study Objectives
This study aims to investigate the efficacy of this probiotic product as an adjuvant therapy alongside lifestyle modifications in adult patients with MASLD. We will evaluate its impact on:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Meet at least one cardiometabolic criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Receive the probiotic product one sachet per day and standard lifestyle modification education for MASLD by a gastroenterologist.
Dietary Supplement: Probiotic product · Behavioral: Life style modification
Receive the placebo one sachet per day and standard lifestyle modification education for MASLD by a gastroenterologist.
Behavioral: Life style modification · Dietary Supplement: placebo
The probiotic product contains Lactobacillus salivarius AP-32, Lactobacillus rhamnosus bv-77, Bifidobacterium animalis CP-9 and Lactobacillus reuteri GL-104
Life style modification of MASLD provided by an gastroenterologist in an outpatient s
placebo sachet looked and taste very similar to the probiotic product being tested
Change in shear wave elastography (m/s) at 12 weeks
Change in liver fibrosis at 12 weeks
Time frame: From enrollment to the end of treatment at 12 weeks
Change in ultrasound attenuation coefficient (dB/cm/MHz) at 12 weeks
Change in liver steatosis at 12 weeks
Time frame: From enrollment to the end of treatment at 12 weeks
Change in blood LDL level (mg/dL) at 12 weeks
Change in blood LDL level (mg/dL) at 12 weeks
Time frame: From enrollment to the end of treatment at 12 weeks
Change in blood HDL level (mg/dL) at 12 weeks
Change in blood HDL level (mg/dL) at 12 weeks
Time frame: From enrollment to the end of treatment at 12 weeks
Change in blood total cholesterol level (mg/dL) at 12 weeks
Change in blood total cholesterol level (mg/dL) at 12 weeks
Time frame: Time Frame: From enrollment to the end of treatment at 12 weeks
Change in blood triglycerides level (mg/dL) at 12 weeks
Change in blood triglycerides level (mg/dL) at 12 weeks
Time frame: From enrollment to the end of treatment at 12 weeks
Change in HOMA-IR at 12 weeks
Change in insulin resistance at 12 week
Time frame: From enrollment to the end of treatment at 12 weeks
Change in blood fasting insulin level (μU/mL) at 12 weeks
Time frame: From enrollment to the end of treatment at 12 weeks
Change in blood fasting glucose level (mg/dL) at 12 weeks
Time frame: From enrollment to the end of treatment at 12 weeks
Change in blood AST level (U/L) at 12 weeks
Change in liver function test
Time frame: From enrollment to the end of treatment at 12 weeks
Change in blood ALT level (U/L) at 12 weeks
Change in liver function test
Time frame: From enrollment to the end of treatment at 12 weeks
Change in blood gamma-GT level (U/L) at 12 weeks
Change in liver function tests
Time frame: From enrollment to the end of treatment at 12 weeks
Change in blood alkaline phosphatase level (IU/L) at 12 weeks
Change in liver function tests
Time frame: From enrollment to the end of treatment at 12 weeks
Change in blood BUN level (mg/dL) at 12 weeks
Change in renal function
Time frame: From enrollment to the end of treatment at 12 weeks
Change in blood Creatinine level (mg/dL) at 12 weeks
Change in renal functions
Time frame: From enrollment to the end of treatment at 12 weeks
Change in eGFR level (mL/min/1.73m^2) at 12 weeks
Change in renal function
Time frame: From enrollment to the end of treatment at 12 weeks
Change in blood albumin level (g/dL) at 12 weeks
Change in liver functions at 12 weeks
Time frame: From enrollment to the end of treatment at 12 weeks
Change in platelet level (*10^3/uL) at 12 weeks
For the calculation of the chane of Fib-4 score at 12 weeks
Time frame: From enrollment to the end of treatment at 12 weeks
Change in HbA1c level (%) at 12 weeks
Change in blood sugar control at 12 weeks
Time frame: From enrollment to the end of treatment at 12 weeks
Change in blood hs-CRP level (mg/L) at 12 weeks
Change in systemic inflammation at 12 weeks
Time frame: From enrollment to the end of treatment at 12 weeks
Change in blood IL-6 level (pg/mL) at 12 weeks
Change in systemic inflammation at 12 weeks
Time frame: From enrollment to the end of treatment at 12 weeks
Change in blood TNF-alpha level (pg/mL) at 12 weeks
Change in systemic inflammation at 12 weeks
Time frame: From enrollment to the end of treatment at 12 weeks
Change in Fib-4 score at 12 weeks
Change in liver fibrosis score at 12 weeks
Time frame: From enrollment to the end of treatment at 12 weeks
Change in ARPI score at 12 weeks
Change in liver fibrosis score at 12 weeks
Time frame: From enrollment to the end of treatment at 12 weeks
Change in NAFLD Fibrosis Score at 12 weeks
Change in liver fibrosis score at 12 weeks
Time frame: From enrollment to the end of treatment at 12 weeks
Change in blood pressures (mmHg) at 12 weeks
Time frame: From enrollment to the end of treatment at 12 weeks
Change in body weight (kg) at 12 weeks
Time frame: From enrollment to the end of treatment at 12 weeks
Change in BMI (kg/m^2) at 12 weeks
Time frame: From enrollment to the end of treatment at 12 weeks
Change in waist circumference (cm) at 12 weeks
Time frame: From enrollment to the end of treatment at 12 weeks
Plan to share: Yes — de-identification data
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Started Apr 2026 (actual). Primary completion is estimated for May 2027, 13 months after the start.
Of 136 non-industry interventional studies with no phase under Fatty Liver, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 13 months is below that.
Counting every sponsor, half of 145 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Probiotic
Fu Jen Catholic University Hospital